Drug intelligence / Profile preview

zorifertinib

Development stage: Phase 3
Lead developer: Alpha Biopharma
Modality: Small Molecules
Administration: Oral

Overview

Zorifertinib (AZD3759) is an orally administered, brain-penetrant small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It was specifically designed to treat non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations. Zorifertinib effectively crosses the blood-brain barrier and inhibits both wild-type and mutant forms of EGFR at nanomolar concentrations. Clinical trials have demonstrated significant improvement in systemic and intracranial progression-free survival compared to first-generation EGFR-TKIs in patients with advanced NSCLC and CNS metastases[1][2][3][5][6][7].

Brand names: Zorifer
Other names: zorifertinib hydrochloride

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on zorifertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zorifertinib.

Explore the full profile